Literature DB >> 9236855

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

S P Henry1, D Monteith, A A Levin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9236855

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN： 0266-9536


× No keyword cloud information.
  10 in total

Review 1.  Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.

Authors:  N Usman; L M Blatt
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  New modalities in oncology: antisense oligonucleotides.

Authors:  C Casey Cunningham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-04

3.  A cytosine analog that confers enhanced potency to antisense oligonucleotides.

Authors:  W M Flanagan; J J Wolf; P Olson; D Grant; K Y Lin; R W Wagner; M D Matteucci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 4.  Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.

Authors:  Gregory Benedetto; C Greer Vestal; Christine Richardson
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

5.  Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.

Authors:  John E Coughlin; Rajendra K Pandey; Seetharamaiyer Padmanabhan; Kathleen G O'Loughlin; Judith Marquis; Carol E Green; Jon C Mirsalis; Radhakrishnan P Iyer
Journal:  Drug Metab Dispos       Date:  2012-02-10       Impact factor: 3.922

6.  Topical antisense-oligonucleotides targeting IFN-gamma mRNA improve incidence and severity of herpetic stromal keratitis by cytokine specific and sequence unspecific effects.

Authors:  Susanne Wasmuth; Dirk Bauer; Klaus-Peter Steuhl; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-11-21       Impact factor: 3.117

7.  Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.

Authors:  Kim Margolin; Timothy W Synold; Primo Lara; Paul Frankel; Simon F Lacey; David I Quinn; Tracey Baratta; Janice P Dutcher; Bixin Xi; Don J Diamond; David R Gandara
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-17       Impact factor: 4.553

8.  Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy.

Authors:  Ingo Roehl; Stephan Seiffert; Celia Brikh; Jonathan Quinet; Catherine Jamard; Nadine Dorfler; Jennifer A Lockridge; Lucyna Cova; Andrew Vaillant
Journal:  Mol Ther Nucleic Acids       Date:  2017-05-04       Impact factor: 8.886

9.  Chemical Modification of CRISPR gRNAs Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells.

Authors:  Mollie S Schubert; Edward Cedrone; Barry Neun; Mark A Behlke; Marina A Dobrovolskaia
Journal:  J Cytokine Biol       Date:  2018-01-29

Review 10.  Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.

Authors:  Marina A Dobrovolskaia; Mark Bathe
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.